Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

La Jolla Pharmaceutical

Status and phase

Terminated

Phase 1

Conditions

Multiple Myeloma

Treatments

Drug: Bortezomib/Dexamethasone

Drug: GCS-100

Study type

Interventional

Funder types

Industry

Identifiers

NCT00609817

PR-CS009

Details and patient eligibility

About

A Phase 1, open-label, dose escalation, multi-center study in patients who have been diagnosed with multiple myeloma and who have relapsed or have refractory/relapsed disease after treatment with at least 2 prior therapies.

Full description

The primary objective of this study is to evaluate the safety and the dose-limiting toxicities of GCS-100 in subjects with relapsed or relapsed/refractory multiple myeloma, and to identify the maximum tolerated dose and/or the recommended dose for further studies.

The secondary objectives of this study are (i) to evaluate the safety of treatment with GCS-100 in combination with bortezomib (VelcadeTM) in subjects whose disease has progressed on GCS-100 alone; (ii) to evaluate the response to GCS-100 alone, in combination with bortezomib in subjects whose disease has progressed on GCS-100 alone, and during dexamethasone therapy in combination with GCS 100 plus bortezomib in subjects whose disease has progressed on GCS-100 plus bortezomib; (iii) to evaluate the utility of potential surrogate markers; (iv) to perform exploratory correlative analyses of bone marrow samples to define better the mechanisms of action and response to therapy.

Enrollment

9 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject is capable of understanding the purpose and risks of the study and is able to provide written Informed Consent.
Subject is male or female, aged at least 18 years.
Subject was diagnosed previously with multiple myeloma based on standard criteria.
Subject has relapsed or relapsed/refractory disease following at least 2 prior therapies and/or lines of therapy (i.e., pre-planned comprehensive treatment regimens). Previously allogeneic and autologous bone marrow transplants, and prior therapy with bortezomib, are permitted.
Subject's Karnofsky performance status is ≥ 60%.
Subject's life expectancy is at least 3 months.
Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least 1 year), and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception throughout the study period.
Subject is willing and able to comply with the prescribed treatment protocol and evaluations.

Exclusion criteria

Subject is receiving concomitant medications (with the exception of bisphosphonates, erythropoietin, and/or up to 10 mg per day of prednisone, and with the exception of up to 100 mg hydrocortisone administered as premedication prior to administration of certain medications or blood products) and/or other therapy that may be active against multiple myeloma. Concurrent radiation therapy is not permitted.
Subject received chemotherapy or other anti-cancer therapy that may be active against multiple myeloma within the 3 weeks prior to Study Day 1, and/or subject received nitrosureas within the 6 weeks prior to Study Day 1.
Subject has not recovered from all toxic effects of previous chemotherapy, radiation therapy, biologic therapy, and/or experimental therapy.
Subject received an investigational therapy within the 3 weeks prior to Study Day 1.
Subject's clinical laboratory values met any of the following criteria within the 7 days prior to Study Day 1:
1. Platelet count < 50,000 cells/mm3
2. Absolute neutrophil count < 1,000 cells/mm3
3. Hemoglobin < 8.0 g/dL (hemoglobin may be maintained by erythropoietin or transfusion)
4. AST and/or ALT > 2.5 X the upper limit of normal
5. Total bilirubin > 1.5 X the upper limit of normal
6. Serum creatinine > 2 mg/dL
Subject has a known history of human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis C infection.
Subject has a clinically relevant active infection and/or a serious co-morbid medical condition such as recent myocardial infarction, unstable angina, difficult-to-control congestive heart failure, uncontrolled hypertension, difficult-to-control cardiac arrhythmias, chronic obstructive or chronic restrictive pulmonary disease, and/or cirrhosis.
Subject had major surgery within the 4 weeks prior to Study Day 1.
Subject had another malignancy within the 3 years prior to study entry, with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, in situ prostate cancer, or other cancer for which the subject has been disease-free for at least the past 3 years.
If female, subject is pregnant or breastfeeding.
Subject has a known hypersensitivity to bortezomib, boron, and/or mannitol.
Subject has a concomitant disease or condition, including laboratory abnormalities, which in the opinion of the Investigator could interfere with the conduct of the study or could put the subject at unacceptable risk.